Blue Cross Blue Shield · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for missing prior authorization by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Diagnosis confirmed by lab tests (e.g., A1C ≥6.5%).

Source policy: Blue Cross Blue Shield tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Blue Cross Blue Shield angle on Tirzepatide

## Blue Cross Blue Shield tirzepatide denials for "prior authorization required" — what's actually happening

A "PA required" denial on tirzepatide (Mounjaro for T2DM, Zepbound for obesity) from a Blue Cross Blue Shield plan is almost never a final adverse determination — it is a utilization management gate instructing the prescriber to submit a coverage request through the plan's PBM. The frustration is that the denial letter rarely names the correct submission channel, and BCBS is a federation of 33 independently licensed plans with divergent PBMs and Medical Policies. Misrouting the PA is the single most common reason these claims sit in limbo for 30+ days.

### Identify the PBM channel before submitting anything

Anthem BCBS plans (14 states) route tirzepatide PA through CarelonRx (formerly IngenioRx). Submit via the CoverMyMeds portal or fax to the Carelon PA unit listed on the back of the member card. Anthem's Clinical Criteria document CC-0001 governs GLP-1/GIP agonists.
BCBS Texas, Illinois, Montana, New Mexico, Oklahoma (HCSC plans) route through Prime Therapeutics. The relevant Prime UM criteria document is "Tirzepatide (Mounjaro, Zepbound)" — current revision 2026.
Independence Blue Cross, Highmark, Horizon BCBS NJ use Express Scripts for most commercial books.
Federal Employee Program (FEP Blue) uses CVS Caremark and applies the FEP-specific Pharmacy Benefit clinical criteria, not the local Blue's MP.

Submitting an Anthem PA to Prime, or a Highmark PA to Carelon, generates an auto-reject that looks like a denial but is actually a routing failure.

### What BCBS expects in the PA packet for T2DM

Most BCBS Medical Policies for tirzepatide (e.g., BCBSNC Pharmacy Policy 1444, BCBS Michigan Drug Policy: GLP-1 Receptor Agonists) require: (1) A1C ≥ 6.5% or two fasting glucose ≥ 126 mg/dL documented in the chart — not just an ICD-10 of E11.9, (2) metformin trial ≥ 90 days at maximally tolerated dose or documented contraindication/intolerance, (3) BMI documented within 90 days, (4) absence of personal/family history of medullary thyroid carcinoma or MEN2, and (5) prescriber attestation the drug will be used with diet/exercise.

### Regulatory leverage when BCBS sits on the PA

Under 29 CFR §2560.503-1(f)(2)(iii)(B), ERISA group plans must resolve non-urgent pre-service PAs within 15 days (extendable once by 15). Urgent PAs are 72 hours. If BCBS misses these, you may treat the claim as deemed exhausted and escalate to external review — cite the deemed-exhaustion rule in your appeal letter. Self-funded ASO plans (most large employer Blues) are ERISA-governed; fully-insured plans add state DOI prompt-pay timelines (e.g., NY DFS 45 days, CA DMHC 5 business days for urgent).

### Tactical tip

Before you fax anything, call the member-card pharmacy-benefit number (not medical) and ask the rep to read back: (a) the exact PBM holding the PA, (b) the current criteria-document number and revision date, and (c) the fax/portal that PBM accepts. Put those three data points in your cover letter — Carelon and Prime reviewers approve faster when the submission references their own document ID.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other insurers on Tirzepatide

Other denial reasons for Blue Cross Blue Shield Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.